A randomized, double-blind, active-controlled study to assess the effect of LCZ696 compared with enalapril to improve exercise capacity in patients with heart failure with reduced ejection fraction (HFrEF).
Phase of Trial: Phase IV
Latest Information Update: 22 Dec 2017
At a glance
- Drugs Sacubitril/valsartan (Primary) ; Enalapril
- Indications Chronic heart failure
- Focus Therapeutic Use
- Sponsors Novartis
- 22 Dec 2017 Last checked against European Clinical Trials Database record.
- 08 Jul 2017 Planned End Date changed from 1 Oct 2017 to 30 Jun 2018.
- 08 Jul 2017 Planned primary completion date changed from 1 Oct 2017 to 30 Jun 2018.